InvestorsHub Logo
Followers 30
Posts 2489
Boards Moderated 1
Alias Born 05/03/2012

Re: alm2 post# 295568

Thursday, 09/03/2020 10:58:06 AM

Thursday, September 03, 2020 10:58:06 AM

Post# of 428737
The sale of the company is the one and only strategy they should pursue. With only one drug this is not a company that can build out an internal pipeline nor have they proven expertise with sales and marketing. They partner the drug in territories not controlled by BP, then file for V approval in territories with value to BP, wait for EU approval, China and Nash results then hire a firm to sell the company. Should be done by December/January with a price between $15 to $20. That is a value of $6 to $8 billion and I would think ROW sales should generate 3 billion a year at peak.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News